NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum

NeOnc Technologies (NASDAQ:NTHI) secured a second UAE IND authorization in June 2026, this time for lead intranasal therapy NEO100 in recurrent high-grade gliomas, covering Phase 1–2 adult and pediatric protocols.

Rhea-AI Summary

NeOnc Technologies (NASDAQ:NTHI) secured a second UAE IND authorization in June 2026, this time for lead intranasal therapy NEO100 in recurrent high-grade gliomas, covering Phase 1–2 adult and pediatric protocols. NEO212 also holds UAE IND status, expanding an international framework that complements U.S. clinical efforts.

NEO100 has FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations. Topline Phase 2a NEO100-01 data are expected by end of July 2026. CEO Amir Heshmatpour recently invested over $500,000 in open-market purchases, with insider buying nearing $1 million in a year. NeOnc also cites access to a $75 million ATM facility and a $10 million credit line, alongside growing institutional interest.

Positive

• Second UAE IND authorization in June 2026 for NEO100 covering Phase 1–2 and pediatric protocols
• Earlier June UAE IND authorization for NEO212 expands international CNS oncology development
• NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations
• Topline NEO100-01 Phase 2a data expected by end of July 2026
• CEO invested over $500,000 recently; insider purchases near $1 million over past year
• Access to $75 million at-the-market facility and $10 million line of credit

Negative

• None.

Argus Jun 24 session

-3.48% close to close Open Argus

Details

News Market Reaction – NTHI

On Jun 24, the day this news came out, NTHI closed 3.48% below the previous close.

Data tracked by StockTitan Argus for the Jun 24 session.

Key Figures

Clinical protocols: three separate clinical protocols Phase 2a timing: end of July 2026 CEO open-market buys: more than $500,000 +3 more

Clinical protocols

three separate clinical protocols

UAE IND authorization for NEO100

Phase 2a timing

end of July 2026

Expected topline NEO100-01 Phase 2a results

CEO open-market buys

more than $500,000

Recent weeks insider purchases by CEO Amir Heshmatpour

Insider buying 1 year

approaching $1 million

Total insider purchases over the past year

ATM facility

$75 million

At-the-market facility referenced in analyst reports

Credit line

$10 million

Line of credit highlighted in analyst commentary

Historical Context

5 past events · Latest: Jun 23

5 events

1. Jun 23

   Regulatory approval

   24h Move

   -4.5%

   UAE IND approval for NEO100 covering multiple protocols plus pediatric pathway.

2. Jun 16

   Regulatory milestone

   24h Move

   +14.9%

   Fresh Abu Dhabi IND for NEO212 and upcoming NEO100 Phase 2a data season.

3. Jun 16

   Clinical trial update

   24h Move

   +14.9%

   UAE IND for NEO212 after Phase 1 completion, enabling global Phase 2 plans.

4. May 29

   AI platform spotlight

   24h Move

   -3.1%

   Profile on NeOnc’s AI‑linked CNS drug delivery and blood‑brain barrier strategy.

5. May 19

   Institutional interest

   24h Move

   -1.5%

   Coverage initiations, insider buying, and institutional accumulation ahead of milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

investigational new drug (ind), orphan drug designation, fast track designation, rare pediatric disease designation, +2 more

6 terms

investigational new drug (ind) regulatory

"securing its second Investigational New Drug (IND) authorization from the United Arab Emirates"

An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.

orphan drug designation regulatory

"NEO100 already carries several important FDA designations, including Orphan Drug Designation"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

fast track designation regulatory

"NEO100 already carries several important FDA designations, including Orphan Drug Designation, Fast Track Designation"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

rare pediatric disease designation regulatory

"and Rare Pediatric Disease Designation. These programs are designed to support the development"

A rare pediatric disease designation is an official regulatory status given to a drug or therapy that targets a serious or life‑threatening condition primarily affecting children and is uncommon in the population. It matters to investors because the status often brings financial and development perks — such as tax credits, reduced fees, faster review and periods of market protection — which can lower costs, speed approval and improve the commercial outlook; think of it as a VIP pass that makes bringing a scarce, child‑focused treatment to market easier and potentially more profitable.

breakthrough therapy designation regulatory

"future regulatory opportunities may include potential consideration for Breakthrough Therapy designation"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

blood-brain barrier medical

"technology platform seeks to address one of the most challenging obstacles in neuro-oncology: the blood-brain barrier"

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NTHI Continues to Build Regulatory Momentum prior to Upcoming Phase 2 Data

DENVER, June 24, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is entering one of the most significant periods in its corporate history after securing its second Investigational New Drug (IND) authorization from the United Arab Emirates this month, further expanding international development opportunities for its central nervous system cancer pipeline.

The latest authorization from the Department of Health – Abu Dhabi grants IND status to NEO100, NeOnc's lead intranasal therapy candidate for recurrent high-grade gliomas. Importantly, the authorization spans three separate clinical protocols, adult studies ranging from Phase 1 through Phase 2, and includes a pediatric development pathway. The approval follows a separate UAE IND authorization for the company's NEO212 program announced earlier in June, marking a rapid expansion of NeOnc's regulatory footprint outside the United States.

For investors following the clinical-stage biotechnology sector, multiple regulatory clearances within a short period can be noteworthy because they potentially create opportunities to accelerate development timelines, expand patient recruitment options, and establish additional pathways toward commercialization. The UAE's growing role as a life sciences and clinical research hub has attracted increasing attention from biotechnology companies seeking global development strategies.

The timing of the NEO100 authorization is particularly notable given that NeOnc expects to report topline results from its fully enrolled NEO100-01 Phase 2a trial by the end of July. The study is evaluating NEO100 in recurrent IDH1-mutant high-grade glioma, one of the most difficult-to-treat forms of brain cancer.

Beyond the UAE approvals, NEO100 already carries several important FDA designations, including Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation. These programs are designed to support the development of therapies targeting serious diseases with significant unmet medical need and may provide opportunities for regulatory efficiencies if future clinical data are supportive.

According to the company, upcoming Phase 2a results could potentially support discussions with regulators regarding additional development pathways. NeOnc has indicated that future regulatory opportunities may include potential consideration for Breakthrough Therapy designation, although any such determination would ultimately rest with the FDA following review of clinical evidence.

Importantly, Chairman, President, and Chief Executive Officer Amir Heshmatpour invested more than $500,000 of personal capital in open-market purchases in recent weeks, with total insider purchases approaching $1 million over the past year according to SEC filings.

Institutional visibility has continued expanding as well. Analyst reports have highlighted the company's access to a $75 million at-the-market facility and a $10 million line of credit, while institutional holders have included major financial firms such as Bank of America, State Street, and Barclays. With additional NEO100 regulatory decisions pending and multiple clinical catalysts expected during 2026, NeOnc remains one of the more closely watched emerging neuro-oncology stories.

NeOnc's underlying technology platform seeks to address one of the most challenging obstacles in neuro-oncology: the blood-brain barrier. NEO100 utilizes a non-invasive intranasal delivery approach designed to transport therapeutic compounds directly to the brain, potentially bypassing limitations associated with conventional systemic therapies.

Meanwhile, NEO212 represents a separate drug-conjugation platform targeting aggressive brain cancers and other malignancies. With both NEO100 and NEO212 now holding active UAE IND authorizations, the company has established a broader international development framework that complements its ongoing U.S. clinical efforts.

As the second half of 2026 begins, NeOnc appears positioned for multiple potential catalysts, including the anticipated Phase 2a data release, possible future FDA interactions, continued international clinical expansion, and advancement of both its NEO100 and NEO212 programs.

For biotechnology investors focused on regulatory milestones and clinical inflection points, the company's recent sequence of regulatory developments may place NeOnc among the more closely watched CNS oncology stories heading into the summer.

About 24/7 Market News

In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor. For the full disclosure, please visit: https://go.247marketnews.com/nthi-disclosure/

For further information, please visit 247marketnews.com.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What UAE drug approvals did NeOnc Technologies (NASDAQ:NTHI) receive for NEO100 in June 2026?

NeOnc received a second UAE Investigational New Drug (IND) authorization in June 2026 for NEO100 in recurrent high-grade gliomas. According to NeOnc, the Abu Dhabi Department of Health approval spans three protocols, including Phase 1–2 adult studies and a pediatric development pathway.

When are the NEO100-01 Phase 2a trial results expected for NeOnc Technologies (NTHI)?

Topline results from NeOnc’s fully enrolled NEO100-01 Phase 2a trial are expected by the end of July 2026. According to NeOnc, this study evaluates intranasal NEO100 in recurrent IDH1-mutant high-grade glioma and could inform future regulatory discussions and development pathways.

What regulatory designations does NEO100 have according to NeOnc Technologies (NTHI)?

NEO100 has Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA. According to NeOnc, these programs are intended to support therapies for serious conditions and may offer regulatory efficiencies if future clinical data are supportive.

How much insider buying has occurred recently in NeOnc Technologies (NASDAQ:NTHI) stock?

NeOnc reports that CEO Amir Heshmatpour invested over $500,000 of personal capital in recent open-market purchases. According to SEC filings cited by NeOnc, total insider purchases have approached $1 million over the past year, potentially signaling management’s alignment with shareholders.

What financing facilities does NeOnc Technologies (NTHI) mention supporting its development programs?

NeOnc highlights access to a $75 million at-the-market (ATM) facility and a $10 million line of credit. According to NeOnc, these resources, alongside growing institutional visibility, support ongoing development of NEO100 and NEO212 within its expanding international and U.S. clinical framework.

How do the UAE IND approvals for NEO100 and NEO212 impact NeOnc Technologies (NTHI)?

The UAE IND approvals for NEO100 and NEO212 broaden NeOnc’s international development options. According to NeOnc, these clearances may help accelerate timelines, expand patient recruitment, and complement U.S. trials as the company advances multiple CNS oncology programs in 2026.